Coming Soon? A New Biologic

Coming Soon? A New Biologic

Coming Soon? A New Biologic For the past two decades, monoclonal antibodies (mAbs) have dominated the biologic drugs market. Doctors use these blockbuster products for a range of diseases, including many cancers and autoimmune diseases. In addition to their...
Biosimilars: Ready or Not, Here They Come

Biosimilars: Ready or Not, Here They Come

Last week, the FDA’s Oncologic Drugs Advisory Committee unanimously recommended Novartis’  biosimilar version of Amgen’s megahit Neupogen (filgrastim), effectively paving the way for the first US biosimilar approval in the near future. Filgrastim is a...